Showing results (421-430 of 531) with videos related to

Sort By:
Pageof 54
Cancer Medicine|May 16, 2026
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active SurveillanceCarolyn Y Fang, Alexander W MacFarlane, Henry C H Fung, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 20, 2022
Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory SettingSunita D Nasta, Mitchell E Hughes, Esin C Namoglu, et al.
Blood Advances|December 12, 2022
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndromeShakthi T Bhaskar, Vivek G Patel, David L Porter, et al.
Clinical and Translational Radiation Oncology|January 31, 2023
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapyNikhil Yegya-Raman, Christopher M Wright, Michael J LaRiviere, et al.
Clinical Transplantation|September 9, 2005
Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorderDonald E Tsai, Nicole A Aqui, John E Tomaszewski, et al.
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 9, 2003
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?Robert M Sharkey, Arnold Brenner, Jack Burton, et al.
Blood|December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomasStephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Pageof 54